Business Wire

NCEC

8.12.2021 01:03:06 CET | Business Wire | Press release

Share
NCEC and OURAY Announce Integrated Emergency Response Support for the Global Market

NCEC, the chemical experts arm of the Ricardo Group , is partnering with OURAY, a global environmental, engineering, manufacturing, and chemical services company, to offer Level One emergency response to OURAY customers, with an emphasis on the Americas and Asia-Pacific regions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005770/en/

OURAY’s customers will receive vital telephone-based advice from the experienced NCEC team in the event of a chemical emergency.

The agreement underpins the APAC Emergency Response initiative, which is due to start in January from OURAY’s new Singapore base, to provide a chemical response service for the Asia-Pacific region. The telephone emergency response (Level 1) will be carried out by NCEC’s best-in-class emergency response service. The on-site expert advice (Level 2) and the on-ground responder (Level 3) service will be provided by OURAY.

Jon Gibbard, Director of NCEC, said: “We have an experienced team of responders who are able to ask appropriate questions to understand the context of the scene, and alongside other sources of information such as SDSs, Chemdata and the responders’ own knowledge, they are able to give proportionate, actionable advice to the caller at the scene of the incident.”

Aaron Montgomery, CHMM/OURAY President and CEO, said: “OURAY is extremely excited about offering these combined services to the marketplace. This OURAY/NCEC partnership will allow our organisations to be the first in the world to provide combined Level 1, 2 and 3 services. This signifies a large step forward in OURAY’s mission to be a complete turn-key solution to the global chemical supply chain.”

Mr Gibbard said: “It is a great opportunity for NCEC/OURAY to support customers with best-in-class emergency response services within the Americas and Asia-Pacific region. We are excited to be working with OURAY. This holistic approach to emergency response further supports our vision to create a world fit for the future by reducing harm from incidents globally. This partnership is a clear indication of how NCEC’s advice-focused approach to emergency response is valued within the market. We are all looking forward to getting started.”

Information for editors

About NCEC

NCEC, part of Ricardo, is a leading provider of chemical emergency response and chemical regulatory support services, enabling customers to reduce the impact their activities have on people and the environment, while protecting their reputation and assets. Offering telephone emergency response, regulatory compliance and policy consultation and hazardous material (hazmat) training, NCEC is the first choice for some of the largest chemical companies across the globe. For more information, visit https://the-ncec.com/

About OURAY

OURAY is a leading and global environmental, engineering, manufacturing and chemical services company, offering solutions in over 100 countries. OURAY helps clients reach their long-term goals, by utilising its knowledge and experience across their global network to assist them with their most pressing needs.

https://www.OURAYservices.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye